Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Work on FcRn inhibition continues apace at Johnson & Johnson (NYSE: JNJ), with more success for nipocalimab. 1 July 2024
Biotechnology
US immunology focused biotech Zenas BioPharma says it has appointed Orlando Oliveira as its chief commercial officer (CCO). 1 July 2024
Biotechnology
Specialty vaccine company Valneva has announced that the European Commission (EC) has granted marketing authorization for its single-dose vaccine, Ixchig, for the prevention of disease caused by the chikungunya virus in people aged 18 years of and older. 1 July 2024
Biotechnology
AstraZeneca’s Marketing Authorization Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients. 1 July 2024
Pharmaceutical
Japanese drugmaker Shionogi announced that the newly-obtained clinical data for the novel COVID-19 oral antiviral Xocova. (ensitrelvir fumaric acid) 1 July 2024
Pharmaceutical
Among important research news last week, US RNA specialist Alnylam Pharmaceuticals released positive Phase III data on its Amvuttra (vutrisiran) in hereditary transthyretin-mediated amyloidosis. On the regulatory front, the US Food and Drug Administration (FDA) approved Verona Pharmaceuticals’ Ohtuvayre for chronic obstructive pulmonary disease (COPD), but US biotech Rocket Pharmaceuticals hit a setback on the development of its gene therapy Kresladi as the FDA issued a complete response letter (CRL). Also of note last week, Denmark’s Novo Nordisk announced a $4.1 billion investment plan in North Carolina, USA, to expand production of treatments for obesity and other chronic diseases. 30 June 2024
Biotechnology
Late-stage US biotech Rocket Pharmaceutical’s shares slumped 12.5% in pre-market activity, but closed down just 2% at $21.10 on Friday after it announced a setback regarding approval of its gene therapy Kresladi (marnetegragene autotemcel; marne-cel). 29 June 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines and one biosimilar for approval at its June 2024 meeting. 28 June 2024
Pharmaceutical
Californian company CalciMedica has announced positive topline data from CARPO, a Phase IIb trial evaluating Auxora in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). 28 June 2024
Biotechnology
It was a milestone achievement when Moderna last month announced its first US Food and Drug Administration (FDA) approval outside COVID-19. 27 June 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze